Digestive Tract Cancer-Related Adverse Events Correlated with Proton Pump Inhibitors Use: A Pharmacovigilance Study of the FDA Adverse Event Reporting System

<div>Forest plot of signal detections for PPIs and digestive tract cancers with subgroup analysis stratified by gender and age. (a) Signal strength for PPIs and H2RAs correlated with digestive tract cancers. (b) Subset analysis stratified by gender. (c) Subset analysis stratified by age. PPIs, proton pump inhibitors; H2RA, H2-receptor antagonist; GNM, gastric neoplasms malignant; PNM, pancreatic neoplasms malignant; BDNM, bile duct neoplasms malignant; SINM, small intestinal neoplasms malignant; ONM, oesophageal neoplasms malignant; CNM, colorectal neoplasms malignant; ACNM, anal canal neoplasms malignant; GBNM, gallbladder neoplasms malignant; HNM, hepatic neoplasms malignant; ROR, reporting odds ratio; CI, confidence interval.</div>

Journal of Clinical Pharmacy and Therapeutics

fig2

Figure 2

Figure 2: Digestive Tract Cancer-Related Adverse Events Correlated with Proton Pump Inhibitors Use: A Pharmacovigilance Study of the FDA Adverse Event Reporting System 

Figure 2 | Digestive Tract Cancer-Related Adverse Events Correlated with Proton Pump Inhibitors Use: A Pharmacovigilance Study of the FDA Adverse Event Reporting System 